Zenith Capital (Zenith Capital) Tax Rate % : 0.00% (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Zenith Capital's Tax Expense for the three months ended in . 20 was $0.00 Mil. Zenith Capital's Pre-Tax Income for the three months ended in . 20 was $0.00 Mil. Therefore, Zenith Capital's Tax Rate % for the quarter that ended in . 20 was 0.00%.

Zenith Capital Tax Rate % Historical Data

The historical data trend for Zenith Capital's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Tax Rate % Chart

Zenith Capital Annual Data

Trend

Tax Rate %

Zenith Capital Quarterly Data

Tax Rate %

Zenith Capital Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Zenith Capital's Tax Rate % for the fiscal year that ended in . 20 is calculated as

Tax Rate %	=	Tax Expense (A: . 20 )	/	Pre-Tax Income (A: . 20 )
	=		/
	=	%

Zenith Capital's Tax Rate % for the quarter that ended in . 20 is calculated as

Tax Rate %	=	Tax Expense (Q: . 20 )	/	Pre-Tax Income (Q: . 20 )
	=		/
	=	%

Zenith Capital Tax Rate % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines